Grace Therapeutics, Inc. (GRCE NASDAQ) stock market data APIs
$3.3228
0.09(2.7%)
as of July 14, 2025
Try our APIs with
free plan!
Grace Therapeutics, Inc. Financial Data Overview
Price chart is built with
Anychart
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Prev. Close
3.3228
Open
3.4107
High
3.7543
Low
3.2743
52 wk Range
1.75-4.97
Market Cap
34 983 K
Shares Outstanding
10 140 K
EPS
0.0464
Beta
1.368
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Grace Therapeutics, Inc. data using free add-ons & libraries
Get Grace Therapeutics, Inc. Fundamental Data
Grace Therapeutics, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -16 663 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-23
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Grace Therapeutics, Inc. News
New
Grace Therapeutics GAAP EPS of -$0.79
* Grace Therapeutics press release [https://seekingalpha.com/pr/20144037-grace-therapeutics-announces-2025-fiscal-year-end-results-provides-business-update] (NASDAQ:GRCE [https://seekingalpha.com/sy...
GRACE THERAPEUTICS Earnings Preview: Recent $GRCE Insider Trading, Hedge Fund Activity, and More
GRACE THERAPEUTICS ($GRCE) is expected to release its quarterly earnings data on Tuesday, June 24th after market close, per Finnhub. Analysts are expecting revenue of $0 and earnings of -$0.32 per sha...
Grace Therapeutics to Participate in the 2025 BIO International Conference
PRINCETON, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, n...
Grace Therapeutics Announces Private Placement Financing of up to $30 Million
Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors $15 million in upfront gross proceeds with the potential ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
